-transparent.png){kind=logo}
This enzyme-radioimmunoassay for the measurement of L-dopa, dopamine, and 3-O-methyldopamine is based on the incubation of urine in the presence of catechol-O-methyltransferase, aromatic-L-amino-acid decarboxylase, and S-adenosylmethionine. The O-methylated dopamine metabolite formed, 3-O-methyldopamine, was characterized by radioimmunoassay. To evaluate the role of L-dopa metabolism in melanoma, we used the enzyme-radioimmunoassay to assess concentrations of L-dopa, dopamine, and 3-O-methyldopamine in urine from 10 healthy subjects, 10 hospitalized patients without melanoma and 28 patients with different degrees of melanoma. The effect of surgery for melanoma on urinary output of these catechols of melanoma patients was also evaluated. No significant difference in urinary L-dopa, dopamine, and 3-O-methyldopamine excretion rates was seen between normal subjects (L-dopa 1.3 +/- 0.3, dopamine 147 +/- 38, and 3-O-methyldopamine 31.4 +/- 13.6 microgram/24 h), hospitalized patients without melanoma, and amelanotic melanoma patients. However, the excretion rates for these metabolites in melanotic melanoma (L-dopa 5.6 +/- 1.2, dopamine 555 +/- 121, and 3-O-methyldopamine 178 +/- 40.3 microgram/24 h) were significantly (p < 0.005) higher than in control or amelanotic melanoma subjects. After surgery, there was a substantial decrease in urinary output of L-dopa and its metabolites by these patients.
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
January 1977,
Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
October 1977,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
November 1974,
Clinical pharmacology and therapeutics,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
November 1974,
Nature,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
September 1972,
Neuropharmacology,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
April 2022,
Analytica chimica acta,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
June 1994,
British journal of pharmacology,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
January 1973,
The American journal of psychiatry,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
November 1995,
British journal of pharmacology,
B A Faraj, and
D H Lawson, and
D W Nixon, and
D R Murray, and
V M Camp, and
F M Ali, and
M Black, and
W Stacciarini, and
Y Tarcan
January 2008,
Neurotoxicity research,
